Literature DB >> 16437660

Upregulation of 25-hydroxyvitamin D(3)-1(alpha)-hydroxylase by butyrate in Caco-2 cells.

Oliver Schröder1, Sinan Turak, Carolin Daniel, Tanja Gaschott, Jürgen Stein.   

Abstract

AIM: To investigate the possible involvement of 25-hydroxyvitamin D(3)-1(alpha)-hydroxylase [1alpha-25(OH) (2) D(3)] in butyrate-induced differentiation in human intestinal cell line Caco-2 cells.
METHODS: Caco-2 cells were incubated either with 3 mmol/L butyrate and 1 micromol/L 25(OH) (2) D(3) or with 1 micromol/L 1alpha-25(OH) (2) D(3) for various time intervals ranging from 0 to 72 h. Additionally, cells were co-incubated with butyrate and either 25(OH) (2) D(3) or 1alpha-25(OH) (2) D(3). 1alpha-25(OH) (2) D(3) mRNA was determined semi-quantitatively using the fluorescent dye PicoGreen. Immunoblotting was used for the detection of 1alpha-25(OH) (2) D(3) protein. Finally, enzymatic activity was measured by ELISA.
RESULTS: Both butyrate and 1alpha-25(OH) (2) D(3) stimulated differentiation of Caco-2 cells after a 48 h incubation period, while 25(OH) (2) D(3) had no impact on cell differentiation. Synergistic effects on differentiation were observed when cells were co-incubated with butyrate and vitamin D metabolite. Butyrate transiently upregulated 1alpha-25(OH) (2) D(3) mRNA followed by a timely delayed protein upregulation. Coincidently, enzymatic activity was enhanced significantly. The induction of the enzyme allowed for comparable differentiating effects of both vitamin D metabolites.
CONCLUSION: Our experimental data provide a further mechanism for the involvement of the vitamin D signaling pathway in colonic epithelial cell differentiation by butyrate. The enhancement of 1alpha-25(OH) (2) D(3) followed by antiproliferative effects of the vitamin D prohormone in the Caco-2 cell line suggest that 25(OH) (2) D(3) in combination with butyrate may offer a new therapeutic approach for the treatment of colon cancer.

Entities:  

Mesh:

Substances:

Year:  2005        PMID: 16437660      PMCID: PMC4725094          DOI: 10.3748/wjg.v11.i45.7136

Source DB:  PubMed          Journal:  World J Gastroenterol        ISSN: 1007-9327            Impact factor:   5.742


  31 in total

1.  1,25-Dihydroxycholecalciferol enhances butyrate-induced p21(Waf1/Cip1) expression.

Authors:  T Gaschott; A Wächtershäuser; D Steinhilber; J Stein
Journal:  Biochem Biophys Res Commun       Date:  2001-04-27       Impact factor: 3.575

2.  Characterization of PicoGreen reagent and development of a fluorescence-based solution assay for double-stranded DNA quantitation.

Authors:  V L Singer; L J Jones; S T Yue; R P Haugland
Journal:  Anal Biochem       Date:  1997-07-01       Impact factor: 3.365

Review 3.  1,25(OH)2-vitamin D3 receptors: gene regulation and genetic circuitry.

Authors:  P P Minghetti; A W Norman
Journal:  FASEB J       Date:  1988-12       Impact factor: 5.191

Review 4.  Antiproliferative action of vitamin D.

Authors:  Timo Ylikomi; Ilkka Laaksi; Yan-Ru Lou; Paula Martikainen; Susanna Miettinen; Pasi Pennanen; Sami Purmonen; Heimo Syvälä; Annika Vienonen; Pentti Tuohimaa
Journal:  Vitam Horm       Date:  2002       Impact factor: 3.421

5.  Vitamin D and its metabolites inhibit cell proliferation in human rectal mucosa and a colon cancer cell line.

Authors:  M G Thomas; S Tebbutt; R C Williamson
Journal:  Gut       Date:  1992-12       Impact factor: 23.059

6.  1,25-Dihydroxyvitamin D3 receptor as a marker of human colon carcinoma cell line differentiation and growth inhibition.

Authors:  M Shabahang; R R Buras; F Davoodi; L M Schumaker; R J Nauta; S R Evans
Journal:  Cancer Res       Date:  1993-08-15       Impact factor: 12.701

7.  p21(WAF1) is required for butyrate-mediated growth inhibition of human colon cancer cells.

Authors:  S Y Archer; S Meng; A Shei; R A Hodin
Journal:  Proc Natl Acad Sci U S A       Date:  1998-06-09       Impact factor: 11.205

8.  Targeting 1alpha,25-dihydroxyvitamin D3 antiproliferative insensitivity in breast cancer cells by co-treatment with histone deacetylation inhibitors.

Authors:  Claire M Banwell; Laura P O'Neill; Milan R Uskokovic; Moray J Campbell
Journal:  J Steroid Biochem Mol Biol       Date:  2004-05       Impact factor: 4.292

9.  Pancreatic cancer cells express 25-hydroxyvitamin D-1 alpha-hydroxylase and their proliferation is inhibited by the prohormone 25-hydroxyvitamin D3.

Authors:  Gary G Schwartz; Dawn Eads; Anuradha Rao; Scott D Cramer; Mark C Willingham; Tai C Chen; Daniel P Jamieson; Lilin Wang; Kerry L Burnstein; Michael F Holick; Constantinos Koumenis
Journal:  Carcinogenesis       Date:  2004-01-23       Impact factor: 4.944

10.  Effects of 1,25-dihydroxyvitamin D3 and its analogs on butyrate-induced differentiation of HT-29 human colonic carcinoma cells and on the reversal of the differentiated phenotype.

Authors:  Y Tanaka; K K Bush; T Eguchi; N Ikekawa; T Taguchi; Y Kobayashi; P J Higgins
Journal:  Arch Biochem Biophys       Date:  1990-02-01       Impact factor: 4.013

View more
  2 in total

1.  Two-stage induced differentiation of OCT4+/Nanog+ stem-like cells in lung adenocarcinoma.

Authors:  Rong Li; Jinsu Huang; Meili Ma; Yuqing Lou; Yanwei Zhang; Lixia Wu; David W Chang; Picheng Zhao; Qianggang Dong; Xifeng Wu; Baohui Han
Journal:  Oncotarget       Date:  2016-10-18

Review 2.  Role of calcium, vitamin D, and the extrarenal vitamin D hydroxylases in carcinogenesis.

Authors:  Julia Höbaus; Ursula Thiem; Doris M Hummel; Enikö Kallay
Journal:  Anticancer Agents Med Chem       Date:  2013-01       Impact factor: 2.505

  2 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.